Market overview
The global over the counter drugs market is worth USD 184 bn in 2026 and is forecast to reach USD 299 bn by 2036, growing at a 5.0% CAGR. United States is the largest country market and Cough, cold and allergy is the largest by category segment.
| Scope | Non-prescription medicines sold over the counter: cough, cold and allergy, pain relief, digestive, skin, eye and sleep products, at retail prices. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 175 bn |
| Value 2026 | USD 184 bn |
| Value 2036 | USD 299 bn |
| CAGR 2026-2036 | 5.0% |
| Volume 2026 | 61,765 million packs |
| Volume 2036 | 82,534 million packs |
| Average price 2026 | USD 2.98 per pack |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Over the Counter Drugs market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 184 bn |
| 2027 | USD 193 bn |
| 2028 | USD 203 bn |
| 2029 | USD 213 bn |
| 2030 | USD 223 bn |
| 2031 | USD 235 bn |
| 2032 | USD 246 bn |
| 2033 | USD 259 bn |
| 2034 | USD 271 bn |
| 2035 | USD 285 bn |
| 2036 | USD 299 bn |
Over the Counter Drugs market segmentation
By category
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cough, cold and allergy | 25.0% | 23.8% | USD 45.9 bn | 4.5% |
| Analgesics | 22.0% | 20.9% | USD 40.4 bn | 4.5% |
| Gastrointestinal | 16.0% | 15.9% | USD 29.4 bn | 5.0% |
| Dermatologicals | 14.0% | 15.3% | USD 25.7 bn | 6.0% |
| Eye, sleep and other | 23.0% | 24.0% | USD 42.3 bn | 5.5% |
By channel
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pharmacies and drugstores | 58.0% | 48.6% | USD 107 bn | 3.2% |
| Supermarkets and mass retail | 20.0% | 16.0% | USD 36.8 bn | 2.7% |
| Online | 22.0% | 35.4% | USD 40.4 bn | 10.1% |
By therapeutic area
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pain relief | 24.0% | 23.0% | USD 44.1 bn | 4.5% |
| Cough and cold | 22.0% | 20.0% | USD 40.4 bn | 4.0% |
| Digestive health | 16.0% | 16.0% | USD 29.4 bn | 5.0% |
| Dermatology | 14.0% | 15.0% | USD 25.7 bn | 5.7% |
| Vitamins and wellness | 24.0% | 26.0% | USD 44.1 bn | 5.8% |
By form
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Tablets and capsules | 48.0% | 44.0% | USD 88.2 bn | 4.1% |
| Liquids and syrups | 20.0% | 19.0% | USD 36.8 bn | 4.5% |
| Topicals | 18.0% | 19.0% | USD 33.1 bn | 5.6% |
| Others combined | 14.0% | 18.0% | USD 25.7 bn | 7.7% |
By brand type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| National brands | 62.0% | 58.0% | USD 114 bn | 4.3% |
| Private label | 24.0% | 26.0% | USD 44.1 bn | 5.8% |
| Store and generic | 14.0% | 16.0% | USD 25.7 bn | 6.4% |
Top 25 countries for over the counter drugs by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 73.5% of 2026 revenue and the 25 countries below together hold 93.6%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 51.5 bn | 28.0% | USD 77.2 bn | 4.1% |
| 2 | China | USD 25.7 bn | 14.0% | USD 51.2 bn | 7.1% |
| 3 | Japan | USD 14.7 bn | 8.0% | USD 20.1 bn | 3.1% |
| 4 | Germany | USD 9.2 bn | 5.0% | USD 13.2 bn | 3.7% |
| 5 | France | USD 6.4 bn | 3.5% | USD 8.7 bn | 3.0% |
| 6 | United Kingdom | USD 6.4 bn | 3.5% | USD 9.3 bn | 3.7% |
| 7 | India | USD 6.4 bn | 3.5% | USD 16.2 bn | 9.7% |
| 8 | Brazil | USD 5.5 bn | 3.0% | USD 9.9 bn | 6.0% |
| 9 | Italy | USD 4.6 bn | 2.5% | USD 6.6 bn | 3.7% |
| 10 | Canada | USD 4.6 bn | 2.5% | USD 6.9 bn | 4.1% |
| 11 | Spain | USD 4.4 bn | 2.4% | USD 9.8 bn | 8.2% |
| 12 | Mexico | USD 4.4 bn | 2.4% | USD 9.8 bn | 8.2% |
| 13 | Australia | USD 4.4 bn | 2.4% | USD 8.3 bn | 6.4% |
| 14 | Russia | USD 4.4 bn | 2.4% | USD 6.5 bn | 3.8% |
| 15 | South Korea | USD 3.8 bn | 2.0% | USD 5.2 bn | 3.4% |
| 16 | Turkey | USD 3.3 bn | 1.8% | USD 4.6 bn | 3.4% |
| 17 | Netherlands | USD 2.8 bn | 1.5% | USD 3.8 bn | 3.3% |
| 18 | Poland | USD 2.2 bn | 1.2% | USD 3.1 bn | 3.3% |
| 19 | Switzerland | USD 1.8 bn | 1.0% | USD 2.5 bn | 3.3% |
| 20 | Indonesia | USD 1.4 bn | 0.7% | USD 1.9 bn | 3.3% |
| 21 | Thailand | USD 1.2 bn | 0.6% | USD 1.6 bn | 3.2% |
| 22 | Argentina | USD 974 mn | 0.5% | USD 1.3 bn | 3.3% |
| 23 | Belgium | USD 735 mn | 0.4% | USD 1.0 bn | 3.3% |
| 24 | Sweden | USD 606 mn | 0.3% | USD 838 mn | 3.3% |
| 25 | Saudi Arabia | USD 478 mn | 0.3% | USD 658 mn | 3.3% |
| Rest of world | USD 11.7 bn | 6.4% | USD 19.3 bn | 5.1% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Haleon
- Kenvue
- Bayer
- Opella
- Reckitt
- Procter and Gamble
Group 2: Regional and specialist players
- Perrigo
- Taisho Pharmaceutical
- Kobayashi Pharmaceutical
- Prestige Consumer Healthcare
- Church and Dwight
- Rohto Pharmaceutical
- Sato Pharmaceutical
- Cooper Consumer Health
- Hisamitsu Pharmaceutical
Group 3: Emerging and niche players
- Dabur
- Himalaya
- Zydus Wellness
- Cipla Health
- Emami
- Ache Laboratorios
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the over the counter drugs market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.0% is calculated from the resulting values.
The market is divided by category, by channel, by therapeutic area, by form, by brand type. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the over the counter drugs market?
The global over the counter drugs market is estimated at USD 175 bn in 2025 and USD 184 bn in 2026.
How fast will the over the counter drugs market grow?
It is forecast to reach USD 299 bn by 2036, a compound annual growth rate of 5.0% from 2026, an increase of USD 116 bn.
Which country is the largest market for over the counter drugs?
United States is the largest market by revenue at USD 51.5 bn in 2026, 28.0% of the global total. The three largest countries together hold 50.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 9.7% a year from 2026 to 2036.
Which over the counter drugs segment is largest?
In the by category split, Cough, cold and allergy is the largest segment with 25.0% of 2026 revenue.
Who are the leading over the counter drugs companies?
Global leaders include Haleon, Kenvue, Bayer, Opella.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Veterinary HealthUSD 187 bn · 7.0% CAGR
- Mail Order PharmacyUSD 172 bn · 7.0% CAGR
- Dietary SupplementUSD 198 bn · 7.0% CAGR
- Hospital SuppliesUSD 200 bn · 5.5% CAGR
- Anti-Neoplastic Pharmaceutical AgentsUSD 239 bn · 9.5% CAGR
- Contract Development and Manufacturing OrganizationUSD 140 bn · 8.0% CAGR
- Active Pharmaceutical IngredientUSD 245 bn · 6.5% CAGR
- Digital HealthUSD 271 bn · 13.0% CAGR
← Otoacoustic Emissions Hearing Screener PET Imaging Workflow →